Seoul: Celltrion Inc. has launched its biosimilar product for Stelara, an autoimmune disease treatment, in the United States: Celltrion Inc., a major South Korean biopharmaceutical firm, announced Thursday the introduction of its latest biosimilar treatment, Steqeyma, in the U.S. market. The new product addresses several conditions, including plaque psoriasis, Crohn's disease, active psoriatic arthritis, and ulcerative colitis.
According to Yonhap News Agency, Steqeyma marks Celltrion's seventh biosimilar product to enter the U.S. market. The U.S. Food and Drug Administration (FDA) granted approval for the drug in both intravenous and subcutaneous forms in December. This development is part of Celltrion's ongoing strategy to strengthen its foothold in the U.S. biosimilar market.
The company has recently secured FDA approvals for multiple biosimilars, such as Avtozma, a biosimilar to Actemra for autoimmune diseases, and Stoboclo and Osenvelt, which are biosimilars to Prolia and Xgeva, respectively. The global market for Stelara is valued at approximately US$10.36 billion, with the U.S. contributing to two-thirds of the global sales. Celltrion aims to expand its portfolio with the commercialization of 22 biosimilar products in international markets by 2030.